http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-202000248-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 2020-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-202000248-A1 |
| titleOfInvention | ANTI-SARS-CoV-2 VIRAL ANTIPROVIR |
| abstract | The invention relates to a new anti-SARS-CoV-2 viral agent Antiprovir, intended for the prevention and treatment of coronovirus disease COVID-19. The use of a pharmaceutical composition, including Aprotex, Gordox and Aerus, including aprotinin and excipients as an active ingredient, as an anti-SARS-CoV-2 viral drug Antiprovir for the prevention and treatment of coronovirus disease COVID-19. The drug Antiprovir for the prevention and treatment of coronovirus disease COVID-19 is a pharmaceutical composition containing 0.1-0.2 wt.% aprotinin, optionally 0.2-1.0 wt.% excipients and the rest is water for injection. |
| priorityDate | 2020-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00974 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16130295 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422600743 |
Total number of triples: 16.